GILEAD AND GALAPAGOS ANNOUNCE POSITIVE EUROPEAN CHMP OPINION FOR JYSELECA (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS - Seite 3
Galapagos Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks, uncertainties and other
factors that could cause actual results to differ materially from those referred to in the forward-looking statements and, therefore, the reader should not place undue reliance on them. These risks,
uncertainties and other factors include, without limitation, the inherent uncertainties associated with competitive developments, clinical trial and product development activities, and regulatory
approval requirements (including that data from the ongoing and planned clinical research programs with filgotinib may not support registration or further development of filgotinib due to safety,
efficacy or other reasons), whether or when regulatory authorities would approve marketing authorization for filgotinib, Galapagos’ reliance on collaborations with third parties (including its
collaboration partner for filgotinib, Gilead), the uncertainty regarding estimating the commercial potential of filgotinib, as well as those risks and uncertainties identified in our Annual Report
on Form 20-F for the year ended December 31, 2019 and our subsequent filings with the SEC. All statements other than statements of historical fact are statements that could be deemed
forward-looking statements. The forward-looking statements contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no
commitment to update or publicly release any revisions to forward-looking statements in order to reflect new information or subsequent events, circumstances or changes in expectations.
# # #
Jyseleca, Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.
Lesen Sie auch
Contacts Galapagos
Investors:
Media:
Elizabeth
Goodwin
Carmen Vroonen